State Street Corp Sells 173,932 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

State Street Corp decreased its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 6.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,485,156 shares of the biopharmaceutical company’s stock after selling 173,932 shares during the quarter. State Street Corp owned about 3.75% of Celldex Therapeutics worth $84,470,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bellevue Group AG boosted its position in shares of Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock worth $104,404,000 after acquiring an additional 100,000 shares during the last quarter. Point72 Asset Management L.P. lifted its position in Celldex Therapeutics by 51.0% during the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after purchasing an additional 654,194 shares during the last quarter. Marshall Wace LLP lifted its position in Celldex Therapeutics by 53.3% during the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after purchasing an additional 479,068 shares during the last quarter. Jennison Associates LLC lifted its position in Celldex Therapeutics by 32.0% during the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after purchasing an additional 321,325 shares during the last quarter. Finally, Novo Holdings A S lifted its position in Celldex Therapeutics by 13.4% during the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after purchasing an additional 113,663 shares during the last quarter.

Analysts Set New Price Targets

CLDX has been the subject of several research reports. Citigroup initiated coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $70.00 price objective for the company. Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $62.25.

Insiders Place Their Bets

In other news, CEO Anthony S. Marucci acquired 11,500 shares of Celldex Therapeutics stock in a transaction on Monday, November 11th. The shares were bought at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at $1,080,416.88. This trade represents a 39.95 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.80% of the stock is currently owned by company insiders.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock opened at $26.20 on Tuesday. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -10.19 and a beta of 1.57. Celldex Therapeutics, Inc. has a 1 year low of $22.93 and a 1 year high of $53.18. The firm has a 50-day moving average of $27.19 and a two-hundred day moving average of $33.58.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.